Welcome to our dedicated page for CapsoVision SEC filings (Ticker: CV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions. These regulatory documents offer detailed insight into the company’s financial condition, risk factors, governance, and product development activities.
CapsoVision’s filings include periodic reports that present net revenue from sales of its CapsoCam Plus capsule endoscopy system, costs of revenue, operating expenses for selling and marketing, research and development, and general and administrative functions, as well as information on cash and cash equivalents and stockholders’ equity. Current Reports on Form 8-K disclose material events such as quarterly financial results, executive appointments or departures, and key regulatory submissions, including applications to the FDA for 510(k) clearance and Breakthrough Device Designation.
On Stock Titan, each new filing from EDGAR is surfaced in near real time and paired with AI-powered summaries that explain the key points in clear language. Instead of reading entire multi-page documents, users can review concise highlights of items such as results of operations, changes in leadership, or updates on clinical and regulatory programs for products like CapsoCam Plus, CapsoCam Colon, and CapsoCam UGI.
Investors can also use this page to locate disclosures related to equity structure, the company’s initial public offering, and compensation or appointment details for senior executives, as reported in 8-K filings. By combining direct access to original SEC documents with AI-generated explanations, this section helps users understand how CapsoVision’s regulatory and financial reporting reflects the evolution of its AI-enabled capsule endoscopy business.
CapsoVision reported a transformative quarter highlighted by a completed IPO and continued operational challenges. The company completed an initial public offering in July 2025, selling 5,629,978 shares at $5.00 per share for gross proceeds of approximately $28.1 million and net proceeds of about $23.4 million. As of June 30, 2025, the company had approximately $1.1 million in cash and an accumulated deficit of $140.4 million. The financials for the six months ended June 30, 2025 show an operating loss of $10,033, a net loss of $10,000, and net cash used in operating activities of $9,512. Management disclosed substantial doubt about going concern.
The company executed a 1-for-3.33 reverse stock split effective July 2, 2025, converted outstanding preferred stock into common stock prior to the IPO, and increased authorized common shares to 300 million. Regulatory and product updates include a 510(k) filing for CapsoCam Colon in Q2 2025 targeting FDA clearance in early 2026 and a development agreement with Canon for CMOS sensors with up to $4.1 million in fees. Material weaknesses in internal controls were identified with remediation in progress.
CapsoVision, Inc. filed a current report to note that it issued a press release on August 14, 2025 announcing its financial results for the fiscal quarter ended June 30, 2025. The company is using this filing to formally furnish that earnings press release as Exhibit 99.1.
The earnings information in the press release is furnished rather than filed, which means it is not automatically incorporated into other securities law filings unless specifically referenced later. The report also identifies the company’s common stock as trading on The Nasdaq Stock Market LLC under the symbol CV.